Bioharvest Sciences Inc. (BHST)
Bioharvest Sciences Inc. reported revenue of 34.5M USD for the year ending 31 December 2025, up 37.0% from 25.2M a year earlier.
Every figure below is the company's own, as filed. Nothing is estimated and
nothing is smoothed — a period the filing does not support is left blank rather than
filled in.
Quarters are the company's own, counted from its financial
year ending 12-31.
Amounts in USD.
The same series drawn ›
As last reported
The newest period the filing supports for each figure, in USD.
| Figure | Period | Amount | Year on year |
|---|
| Revenue |
2025 · ending 31 December 2025 |
34.5M |
+37.0% |
| Gross Profit |
2025 · ending 31 December 2025 |
20.5M |
+46.9% |
| Operating Income |
2025 · ending 31 December 2025 |
-5.6M |
— |
| Net Income |
2025 · ending 31 December 2025 |
-11.1M |
— |
| Cost of Revenue |
2025 · ending 31 December 2025 |
14M |
+24.8% |
| Operating Cash Flow |
2025 · ending 31 December 2025 |
-7.2M |
— |
| Free Cash Flow |
2025 · ending 31 December 2025 |
-9.6M |
— |
| EPS |
2025 · ending 31 December 2025 |
-0.60 |
— |
Revenue and profit by financial year
As filed, in USD. A year the filing does not support is not listed.
| Year | Ending |
Revenue | Operating Income | Net Income | Free Cash Flow |
|---|
| 2025 | 2025-12-31 |
34.5M | -5.6M | -11.1M | -9.6M |
|---|
| 2024 | 2024-12-31 |
25.2M | -7M | -12.9M | -9.5M |
|---|
| 2023 | 2023-12-31 |
12.7M | -10M | -12.6M | -10M |
|---|
Every period
Revenue Annual
| Period | Ending | Revenue |
|---|
| FY25 | 2025-12-31 | 34.5M |
|---|
| FY24 | 2024-12-31 | 25.2M |
|---|
| FY23 | 2023-12-31 | 12.7M |
|---|
Gross Profit Annual
| Period | Ending | Gross Profit |
|---|
| FY25 | 2025-12-31 | 20.5M |
|---|
| FY24 | 2024-12-31 | 13.9M |
|---|
| FY23 | 2023-12-31 | 5.6M |
|---|
Operating Income Annual
| Period | Ending | Operating Income |
|---|
| FY25 | 2025-12-31 | -5.6M |
|---|
| FY24 | 2024-12-31 | -7M |
|---|
| FY23 | 2023-12-31 | -10M |
|---|
Net Income Annual
| Period | Ending | Net Income |
|---|
| FY25 | 2025-12-31 | -11.1M |
|---|
| FY24 | 2024-12-31 | -12.9M |
|---|
| FY23 | 2023-12-31 | -12.6M |
|---|
Cost of Revenue Annual
| Period | Ending | Cost of Revenue |
|---|
| FY25 | 2025-12-31 | 14M |
|---|
| FY24 | 2024-12-31 | 11.2M |
|---|
| FY23 | 2023-12-31 | 7M |
|---|
Operating Cash Flow Annual
| Period | Ending | Operating Cash Flow |
|---|
| FY25 | 2025-12-31 | -7.2M |
|---|
| FY24 | 2024-12-31 | -6.7M |
|---|
| FY23 | 2023-12-31 | -8.5M |
|---|
Free Cash Flow Annual
Operating cash flow minus capital expenditure.
| Period | Ending | Free Cash Flow |
|---|
| FY25 | 2025-12-31 | -9.6M |
|---|
| FY24 | 2024-12-31 | -9.5M |
|---|
| FY23 | 2023-12-31 | -10M |
|---|
EPS Annual
The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.
| Period | Ending | EPS |
|---|
| FY25 | 2025-12-31 | -0.60 |
|---|
| FY24 | 2024-12-31 | -0.80 |
|---|
| FY23 | 2023-12-31 | -0.93 |
|---|